Scarica l'app Stockscreener
0.00
2.94%
-0.102
Precedente Chiudi:
$0.102
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-20.62M
Rapporto P/E:
0.00
EPS:
-18.54
Flusso di cassa netto:
$-17.61M
1 W Prestazione:
-2.94%
1M Prestazione:
-22.22%
6M Prestazione:
-74.07%
1 anno Prestazione:
+623.57%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$0.00
Neximmune Inc Stock (NEXI) Company Profile
Confronta NEXI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEXI
Neximmune Inc
|
0.00 | 0 | 0 | -20.62M | -17.61M | -18.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.99 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.12 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
411.00 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
676.92 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
301.95 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Neximmune Inc Stock (NEXI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-01 | Iniziato | Raymond James | Outperform |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-03-09 | Iniziato | Cantor Fitzgerald | Overweight |
Neximmune Inc Borsa (NEXI) Ultime notizie
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire UK
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Analyzing Theratechnologies (NASDAQ:THTX) and NexImmune (NASDAQ:NEXI) - Defense World
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
Vanotech Appoints Matthew Schiller to Lead Business Development - citybiz
Vanotech appoints Matthew Schiller to Lead Business Development - EFECOMUNICA
Reviewing NexImmune (NASDAQ:NEXI) & Benitec Biopharma (NASDAQ:BNTC) - Defense World
NexImmune (NASDAQ:NEXI) Stock Price Down 15.2% – Should You Sell? - Defense World
North American Morning Briefing : Tesla, Chip -2- -January 03, 2025 at 06:08 am EST - Marketscreener.com
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace
NexImmune moves forward with wind-down process - The Business Journals
NexImmune Dissolution Progresses with New Sole President - TipRanks
NexImmune shareholders approve company dissolution - Investing.com
What Are the Rules Behind the Delisting of a Stock? - Investopedia
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
What Is Going on With NexImmune (NEXI) Stock Today? - InvestorPlace
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
NexImmune Ends Stock Sale Agreement, Raises $5.1 Million - TipRanks
Neximmune terminates equity sales agreement and ATM program - TipRanks
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Stock Titan
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation - TradingView
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
NexImmune's future in limbo as Gaithersburg biotech extends liquidation vote - The Business Journals
NEXI Stock Halted: What’s Going on With NexImmune Shares Today? - InvestorPlace
Gaithersburg biotech prepares to shut down, lay off ‘substantially all’ employees - The Business Journals
Gaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employees - The Business Journals
Why Neximmune (NEXI) Stock Is Getting Hammered - TradingView
Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq - The Business Journals
D.C.'s Vanda Pharmaceuticals to ask Supreme Court to review patent infringement lawsuit - The Business Journals
NexImmune (NASDAQ: NEXI) to jump 2,500% todaya purely technical move - Dhaka Tribune
NexImmune to lay off over half of its employees - Pharmaceutical Technology
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy - Stock Titan
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT). - ASCO Publications
Sirnaomics spinout RNAImmune launching clinical trial for Covid-19 vaccine booster - The Business Journals
Gaithersburg biotech Salubris Biotherapeutics clinches $35M investment for R&D - The Business Journals
Silver Spring's Aziyo Biologics laying off 12% of workforce - The Business Journals
Why NexImmune (NEXI) Shares Are Trading Higher TodayNexImmune (OTC:NEXI) - Benzinga
Barer Sol J Increases Position in NexImmune (NEXI) - Nasdaq
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’ - insights.citeline.com
AIM™ platform: A new immunotherapy approach for viral diseases - Frontiers
Life Sciences Firm Closing 2 Maryland Facilities, Laying Off Workers - Bisnow
Analyst Downgrades NexImmune After Going Back To Preclinical Stage - Yahoo Finance
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders - Business Wire
Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies - GlobeNewswire
Global Human Papillomavirus Associated Cancer Pipeline - GlobeNewswire
Zephyr AI Announces Additions to the Board of Directors - Business Wire
Pharma50: 50 Leading Cell and Gene Therapy Companies - drugdiscoverytrends.com
What Makes NexImmune, Inc. (NEXI) a New Buy Stock - Nasdaq
NexImmune Appoints Dr. Leena Gandhi To Board - citybiz
Neximmune Inc Azioni (NEXI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.31%
Capitalizzazione:
|
Volume (24 ore):